APP and Alzheimer disease: Pharmacological or genetic inhibition of RIPK1 kinase reduces neuroinflammation, amyloid burden, and memory deficits in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model of AD [93].